ライフサイエンスコーパス: amiodarone

1 patients off medication (except 1 patient on amiodarone).

2 33 to 0.99] for ICD; 0.44 [0.24 to 0.80] for amiodarone).

3 r high-risk medications (eg, spironolactone, amiodarone).

4 odrugs elicit bradycardia when combined with amiodarone.

5 reated patients and patients who were not on amiodarone.

6 were compared with those who did not receive amiodarone.

7 e in the recipient pretransplantation use of amiodarone.

8 One patient in each group was on amiodarone.

9 ay, and non-CV death were more frequent with amiodarone.

10 he efficacy and safety of dronedarone versus amiodarone.

11 miodarone, and 1 trial of dronedarone versus amiodarone.

12 l and patient specific factors on the use of amiodarone.

13 drug; 8,883 (60%) of these patients received amiodarone.

14 c drug; 108 (40%) of these patients received amiodarone.

15 inescence demonstrate a biphasic response to amiodarone.

16 I antiarrhythmic drugs, and 62 (22%) were on amiodarone.

17 inhibitors may exhibit this cardiac DDI with amiodarone.

18 on and recent studies have shown promise for amiodarone.

19 entifying patients eligible for prophylactic amiodarone.

20 aining 36 (66%) did so spontaneously or with amiodarone.

21 nge 8 weeks after the patient stopped taking amiodarone.

22 terol is correlated with the accumulation of amiodarone.

23 uvir and daclatasvir by 2 patients receiving amiodarone.

24 odarone-treated patients and patients not on amiodarone.

25 In all, 16 (4.1%) amiodarone, 11 (3.1%) lidocaine, and 6 (1.9%) placebo-tr

26 ion consisted mostly of beta-blockers (38%), amiodarone (14%), or sotalol (30%).

27 Amiodarone (200 mg/d after loading dose of 600 mg/d for

28 6%), diltiazem (22.7%), digoxin (22.5%), and amiodarone (21.1%).

29 ad persistent atrial fibrillation to receive amiodarone (267 patients), sotalol (261 patients), or pl

30 is against POAF with beta-blockers (85%) and amiodarone (28%) was allowed on the basis of caregivers'

31 .6% (1.1% to 4.1%) in patients randomized to amiodarone, 3.2% (1.8% to 4.7%) in patients randomized t

32 amiodarone infusion, or a 60-min infusion of amiodarone (5 mg/kg) followed by a maintenance infusion

33 irst CVH event rates at 3 years were 47% for amiodarone, 50% for sotalol, and 44% for Class 1C versus

34 higher rate of symptom relief compared with amiodarone (53.4% of vernakalant patients reported no AF

35 ic range that was lower than patients not on amiodarone (56.5% vs. 63.0%; p < 0.0001).

36 bo (847 patients), conventional therapy plus amiodarone (845 patients), or conventional therapy plus

37 ion, 3026 patients were randomly assigned to amiodarone (974), lidocaine (993), or placebo (1059); of

38 ncomitant prophylaxis with beta-blockers and amiodarone, a multicenter, randomized, double-blind tria

39 cellular uptake of the antiarrhythmic agent amiodarone, a phospholipidosis-inducing pharmaceutical c

40 icular tachycardia/ventricular fibrillation, amiodarone (adjusted hazard ratio 0.39, 95% confidence i

41 iently expressing human SK2 before and after amiodarone administration.

42 Amiodarone also caused rapid nuclear accumulation of the

43 idocaine, while 67% of children who received amiodarone also received lidocaine (p < .001).

44 e percent of adults with VF/pVT who received amiodarone also received lidocaine, while 67% of childre

45 Desethylamiodarone, a major metabolite of amiodarone, also exerts voltage-independent but Ca(2+) d

46 tion between nitrophenols (pi-acceptors) and amiodarone (AM) was performed using electronic absorptio

47 Amiodarone (AMD) and nifekalant (NIF) are used in the tr

48 hether catheter ablation (CA) is superior to amiodarone (AMIO) for the treatment of persistent atrial

49 tivirals (DAAs) and the antiarrhythmic drug, amiodarone (AMIO).

50 The amiodarone analog N-ethylamiodarone (NEA) did not alter

51 Both amiodarone and desethylamiodarone inhibit I KAS at thera

52 azine may be of benefit as an alternative to amiodarone and dofetilide in the management of AF in pat

53 ase (CVD), pregnancy, and in patients taking amiodarone and isotretinoin.

54 e further confirmed by the autophagy inducer amiodarone and miR-224 antagonist using an orthotopic SD

55 biomicroscopy), and serum concentrations of amiodarone and N-desethylamiodarone also were determined

56 Amiodarone and propranolol were stopped, but the patient

57 The second patient was taking amiodarone and propranolol; 2 hrs after receiving sofosb

58 Amiodarone and sotalol are equally efficacious in conver

59 In 256 patients randomized between amiodarone and sotalol, 60% versus 38% were successfully

60 s was used to assess the association between amiodarone and the occurrence of optic neuropathy.

61 th main effects for randomized treatment and amiodarone and their interaction.

62 with those who qualified but did not receive amiodarone and those not evaluated (11.1% versus 38.7% a

63 brillation were randomly assigned to receive amiodarone and undergo two cardioversions during the fir

64 dronedarone, 4 placebo-controlled trials of amiodarone, and 1 trial of dronedarone versus amiodarone

65 diation, drugs such as lithium carbonate and amiodarone, and pituitary and hypothalamic disorders.

66 ess of left atrial catheter ablation (LACA), amiodarone, and rate control therapy in the management o

67 ed with different concentrations of the drug amiodarone, and we observed that the upregulation of pho

68 At 5 years, the amiodarone arm had a survival rate equivalent to that of

69 s (11 for atrial arrhythmias), and 2 were on amiodarone as a bridge to heart transplantation.

70 rillation and in those patients who received amiodarone as compared with lidocaine.

71 In children, the overall efficacy of IV amiodarone, as measured by time to success, was dose rel

72 Hek 293 have a significantly lower amount of amiodarone at 0.43 and 0.36 pg per cell, respectively.

73 ine characteristics of patients who received amiodarone at randomization were compared with those who

74 n ARISTOTLE, 2,051 (11.4%) patients received amiodarone at randomization.

75 atients who received and who did not receive amiodarone at the time of randomization.

76 Use of amiodarone before transplant was associated with a nonsi

77 rence of LAE before and after treatment with amiodarone, beta-blockers, sotalol, or ablation.

78 Patients newly treated with amiodarone between 2005 and 2009 were identified from th

79 rrhythmic agent pharmacologically related to amiodarone but developed to reduce the risk of side effe

80 of nutrient-responsive genes was affected by amiodarone but not CaCl(2), indicating that activation o

81 lar accumulation of L-ala,SP metabolites +/- amiodarone, but no D-ala,RP metabolites were detected.

82 /ventricular fibrillation who survive 3 hrs, amiodarone, but not lidocaine, is associated with an inc

83 transcriptional response of S. cerevisiae to amiodarone by DNA microarray.

84 Amphiphilic medications (amiodarone, chloroquine, suramin, clofazimine, etc.) may

85 ference in all-cause hospitalization between amiodarone, Class Ic, and sotalol.

86 Amiodarone or amiodarone combinations converted 14 of 15 (93%) with re

87 The corresponding HRs for amiodarone compared to placebo were 0.68 (95% CI: 0.46 t

88 In conclusion, amiodarone competes with NEA at a novel, extracellular,

89 Dronedarone is a noniodinated amiodarone congener developed to maintain sinus rhythm.

90 Pretreatment with amiodarone did not increase the success rates.

91 alone: 38.09 for NOAC use alone vs 52.04 for amiodarone (difference, 13.94 [99% CI, 9.76-18.13]); 102

92 5 in an independent replication cohort of 28 amiodarone dLQTS cases versus 173 control subjects (meta

93 Similar to amiodarone, dronedarone is a potent blocker of multiple

94 bolite formation, yet exacerbated L-ala,SP + amiodarone effects, implicating the prodrugs in these ef

95 Amiodarone enhanced the maximal level of agonist-stimula

96 of optic neuropathy in patients treated with amiodarone, especially in males and possibly in patients

97 vular atrial fibrillation, concurrent use of amiodarone, fluconazole, rifampin, and phenytoin compare

98 Concurrent use of amiodarone, fluconazole, rifampin, and phenytoin with NO

99 atorvastatin; digoxin; verapamil; diltiazem; amiodarone; fluconazole; ketoconazole, itraconazole, vor

100 Sotalol for atrial flutter, and digoxin and amiodarone for 1: 1 reciprocating tachycardia.

101 transplacentally with a loading dose of oral amiodarone for 2 to 7 days, followed by daily maintenanc

102 ernakalant demonstrated efficacy superior to amiodarone for acute conversion of recent-onset AF.

103 ostoperative atrial arrhythmias; intravenous amiodarone for destabilizing ventricular arrhythmias; an

104 atients received digoxin, beta-blockers, and amiodarone for rate control; device interrogation showed

105 cy and safety of intravenous vernakalant and amiodarone for the acute conversion of recent-onset atri

106 Dronedarone is less effective than amiodarone for the maintenance of sinus rhythm, but has

107 quantitative measurements of cell-associated amiodarone for the population using LC/MS/MS and cell co

108 n which the authors evaluated dronedarone or amiodarone for the prevention of AF.

109 he efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent atrial fibril

110 synthesize evidence regarding optimal use of amiodarone for various arrhythmias.

111 tal diameter was significantly higher in the amiodarone group compared with the control group (AK gro

112 However, only 14 patients (25%) in the amiodarone group received the recommended initial 300-mg

113 s conversion occurred in 27.1 percent of the amiodarone group, 24.2 percent of the sotalol group, and

114 of atrial fibrillation were 487 days in the amiodarone group, 74 days in the sotalol group, and 6 da

115 n the placebo group, 240 (28 percent) in the amiodarone group, and 182 (22 percent) in the ICD group.

116 00-mg groups, respectively; and 45.3% in the amiodarone group.

117 pixaban with warfarin, patients who received amiodarone had a stroke or a systemic embolism rate of 1

118 oderately symptomatic heart failure, whereas amiodarone had no benefit on mortality rates.

119 Amiodarone had no effect on all-cause mortality or its c

120 Compared with placebo, amiodarone had no significant effect on any mode of deat

121 The use of amiodarone had no significant effects on the primary qua

122 Amiodarone had the lowest risk of AF hospitalization and

123 Patients on warfarin and amiodarone had time in the therapeutic range that was lo

124 However, amiodarone has a number of serious adverse effects, incl

125 The antiarrhythmic drug amiodarone has fungicidal activity against a broad range

126 Amiodarone has gained recognition as an antiarrhythmic m

127 I or III CHF and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas

128 Intravenous (IV) amiodarone has proven efficacy in adults.

129 rom a small number of patients suggests that amiodarone has superior efficacy in preventing ventricul

130 owed better outcomes with Rate compared with amiodarone (hazard ratio [HR]: 1.18, 95% confidence inte

131 s 40%, 40%, and 36%, respectively, for Rate (amiodarone HR: 1.20, 95% CI: 1.03 to 1.40, p = 0.02, sot

132 R] 1.59; 95% confidence interval 1.13-2.24), amiodarone (HR 2.63; 1.77-3.89), and sotalol (HR 1.72; 1

133 a nonsignificant increase in mortality with amiodarone (HR: 1.20, 95% CI: 0.94 to 1.53, p = 0.15) wi

134 ive care unit stay or death was shorter with amiodarone (HR: 1.22, 95% CI: 1.02 to 1.46, p = 0.03).

135 ent arms (ICD, HR 1.54, 95% CI 1.04 to 2.27; amiodarone, HR 1.33, 95% CI 0.91 to 1.93; and placebo, H

136 ate heart failure were randomized to receive amiodarone, implanted cardioverter-defibrillators (ICDs)

137 mean of 2.4 antiarrhythmic drugs, including amiodarone in 29 (47%) patients.

138 upon accidental intra-arterial injection of amiodarone in an emergency setting.

139 ive magnesium and steroids, and preoperative amiodarone in high-risk patients should be rigorously ev

140 hod that has been shown to enable imaging of amiodarone in single rat macrophage (NR8383) cells.

141 hase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrilla

142 ion of landmark studies and the inclusion of amiodarone in the American Heart Association Guidelines

143 usion or exclusion of patients randomized to amiodarone in the analyses.

144 clinical events and bleeding with the use of amiodarone in the ARISTOTLE (Apixaban for Reduction in S

145 nadequate dosing and later administration of amiodarone in the code were two confounding factors in t

146 oup difference, with earlier prescription of amiodarone in the placebo group (P=0.022).

147 median of 2 antiarrhythmic drugs), including amiodarone, in 166 (59%) patients.

148 Amiodarone increased atrial APD and reduced APD heteroge

149 Overnight treatment with amiodarone increased the fat content by approximately 2-

150 approach to the management of patients with amiodarone-induced alterations in thyroid function tests

151 fusion (2 mg/kg) if still in AF, plus a sham amiodarone infusion, or a 60-min infusion of amiodarone

152 pendent, but was Ca(2+)-dependent: 30 microM amiodarone inhibited 81.5+/-1.9% of I KAS induced with 1

153 Amiodarone inhibited IKAS in a dose-dependent manner (IC

154 We have reported previously that amiodarone interacts with muscarinic receptors via a nov

155 Amiodarone is a medication that was added to the pediatr

156 Amiodarone is an effective medication in preventing atri

157 Although amiodarone is approved by the US Food and Drug Administr

158 Amiodarone is effective in maintaining sinus rhythm in a

159 The only role for prophylactic amiodarone is in the perioperative period of cardiac sur

160 Orally administered amiodarone is safe and effective treatment for drug-refr

161 Amiodarone is superior for maintaining sinus rhythm, but

162 Amiodarone is the most effective antiarrhythmic drug for

163 Amiodarone is useful in acute management of sustained ve

164 mpflug corneal densitometry in patients with amiodarone keratopathy (AK).

165 Co-applied with amiodarone, L-ala,SP prodrugs increased beating rate and

166 , double-blind trial, we compared parenteral amiodarone, lidocaine, and saline placebo, along with st

167 ctively randomized, double-blind, to receive amiodarone, lidocaine, or placebo by paramedics.

168 ere delivered urgently in tachycardia during amiodarone loading, and 3 required additional antiarrhyt

169 The clinical efficacy and toxicity of amiodarone may be determined more effectively by tissue

170 Amiodarone may be effective as an adjunct to implantable

171 Amiodarone may have clinical value in patients with left

172 ditions and nitrogen depletion suggests that amiodarone may interfere with nutrient sensing and regul

173 We revealed Amiodarone-mediated QTc prolongation, HR reduction and H

174 btained when the macrophages were doped with amiodarone metabolite, desethylamiodarone.

175 Those on amiodarone (n = 10) had a significantly lower risk of an

176 atients received lidocaine (n = 664, 59.0%), amiodarone (n = 50, 4.4%), both (n = 110, 9.8%), or no a

177 ted with antiarrhythmic drugs (most commonly amiodarone [n=103] or sotalol [n=78]) and AF catheter ab

178 for inclusion (n=79 for lidocaine, n=74 for amiodarone, n=41 for combination).

179 Overall, neither amiodarone nor lidocaine resulted in a significantly hig

180 mes were published before the routine use of amiodarone or ablation therapies.

181 Amiodarone or amiodarone combinations converted 14 of 15

182 Treatment with amiodarone or an implantable cardioverter-defibrillator

183 nhibitor or beta-blocker therapy, and use of amiodarone or digoxin (area under the ROC curve of 0.66)

184 t PVCs and DCM were substantially reduced by amiodarone or flecainide, which are drugs that have sodi

185 redictors of thromboembolism; treatment with amiodarone or ICD treatment was a significant predictor

186 Those treated with amiodarone or ICDs had lower risk of thromboembolism tha

187 nt estimates for survival were greater after amiodarone or lidocaine than placebo, without increased

188 randomly assigned 2521 patients to placebo, amiodarone, or ICD between 1997 and 2001.

189 D-HeFT regardless of treatment arm (placebo, amiodarone, or ICD).

190 CD-HeFT randomized 2521 subjects to placebo, amiodarone, or shock-only, single-lead ICD therapy.

191 nction, or concomitant use of beta-blockers, amiodarone, or warfarin.

192 g increasing INR (antiarrhythmics class III [amiodarone], other opioids [tramadol], glucocorticoids,

193 alant patients compared with 6 of 116 (5.2%) amiodarone patients (p < 0.0001).

194 Seven hundred twenty-nine amiodarone patients, 606 sotalol patients, and 268 Class

195 AF symptoms at 90 min compared with 32.8% of amiodarone patients; p = 0.0012).

196 Settings in which amiodarone prophylaxis against atrial fibrillation after

197 Trials that assessed whether amiodarone prophylaxis decreases the incidence of postop

198 Amiodarone prophylaxis decreases the occurrence of atria

199 More amiodarone recipients required temporary cardiac pacing

200 ects similar to those observed after chronic amiodarone (reduced I(Kr), I(Ks), late I(Na), and I(Ca))

201 Among antiarrhythmic drugs, only amiodarone reduces VAs, although its use may be associat

202 Amiodarone-related adverse effects were transient in 5 i

203 Overall, the transcriptional responses to amiodarone revealed by this study were found to be disti

204 SK2 current inhibition may in part underlie amiodarone's effects in preventing electrical storm in f

205 that reserve by receptor alkylation unmasked amiodarone's enhancement of the maximal IP response to a

206 Amiodarone, sedation, sodium channel-blocking agents, an

207 (Cch1/Mid1 and Yvc1), and exchangers (Vcx1), amiodarone sensitivity correlates with cytoplasmic calci

208 ver additional cellular pathways involved in amiodarone sensitivity, we conducted a genome-wide scree

209 rvations indicate that patients treated with amiodarone should be continuously monitored within the f

210 y ill patients, the dose-related risks of IV amiodarone should be taken into account when treating ch

211 Amiodarone should be used with close follow-up in patien

212 effectiveness (in the rate-control group) or amiodarone side effects or adverse drug reactions (in th

213 Amiodarone, sofosbuvir, and daclatasvir treatment were s

214 e who received their first AAD prescription (amiodarone, sotalol, dronedarone, or Class Ic) within 14

215 ersistent AF were randomized double-blind to amiodarone, sotalol, or placebo.

216 Drug treatment with beta-blockers, amiodarone, statins, steroids, magnesium, and sotalol ca

217 model incorporating all trial evidence found amiodarone superior to dronedarone (OR: 0.49; 95% CI: 0.

218 A moderate dose of amiodarone temporarily delayed cell cycle progression at

219 ardiovascular hospitalization was lower with amiodarone than Class Ic (HR 0.80; 0.70-0.92), but not n

220 y have different benefits from lidocaine and amiodarone than previously demonstrated.

221 e is a noniodinated benzofuran derivative of amiodarone that has been developed for the treatment of

222 In patients who did not receive amiodarone, the stroke or systemic embolism rate was 1.2

223 nsive care units (< or = 50 beds) to receive amiodarone; the association persisted in multivariable a

224 nce of atrial fibrillation was 569 days with amiodarone therapy and 428 days with sotalol therapy (P=

225 Sixty-six patients receiving amiodarone therapy and 66 healthy controls were consecut

226 roup of SCD-HeFT patients who were harmed by amiodarone therapy and did not benefit from ICD.

227 st patients have complete VT control without amiodarone therapy and limited need for antiarrhythmic d

228 aluates the safety, efficacy, and outcome of amiodarone therapy for digoxin-refractory fetal tachycar

229 data from 10 trials involving 1744 patients, amiodarone therapy was found to decrease the incidence o

230 found significantly more adverse events with amiodarone therapy, including nausea permitting continua

231 or quantifying AK and can help in monitoring amiodarone therapy.

232 achycardia of 190 beats/min was administered amiodarone through an accidently placed arterial access

233 nd device-based interventions such as adding amiodarone to baseline beta-blocker therapy, adjusting I

234 nal period, optic neuropathy developed in 17 amiodarone-treated patients (0.3%) and 30 control patien

235 The analysis included 6175 amiodarone-treated patients and 24 700 controls.

236 ted, but were not significantly different in amiodarone-treated patients and patients not on amiodaro

237 and major bleeding compared with warfarin in amiodarone-treated patients and patients who were not on

238 ivariate Cox regression analysis showed that amiodarone-treated patients had a 2-fold increased risk

239 More amiodarone-treated patients had a stroke or a systemic e

240 Among amiodarone-treated patients, male gender was associated

241 genesis was markedly reduced indicating that amiodarone treatment induces insulin resistance.

242 cipient African American race, and recipient amiodarone treatment.

243 matched control subjects who did not receive amiodarone treatment.

244 lation of the European Myocardial Infarction Amiodarone Trial (EMIAT).

245 Amiodarone use and hospitalization decreased from 55% an

246 teady 3-year nonrecurrence rate with reduced amiodarone use and hospitalizations indicate improved lo

247 The interaction p values for amiodarone use by apixaban treatment effects were not si

248 To examine practice patterns of amiodarone use during in-hospital cardiac arrest.

249 There has been a significant increase in amiodarone use for VF/pVT events over the past 5 yrs.

250 In adults, amiodarone use for VF/pVT increased from 25% in 2000 to

251 The frequency of amiodarone use in adults correlated positively with the

252 This study addresses the changing pattern of amiodarone use over time, following the publication of l

253 After stratification by gender, amiodarone use remained a significant factor for optic n

254 Amiodarone use was associated with significantly increas

255 rea [BSA], chronic kidney disease [CKD], and amiodarone use) and genetic factors (CYP2C9*2, *3, *5, *

256 rfarin dose was influenced by age, BSA, CKD, amiodarone use, and CYP2C9*3 and VKORC1 variants in both

257 , serum creatinine concentration, digoxin or amiodarone use, and QRS duration near 130-ms peak.

258 standard dose versus high-dose epinephrine, amiodarone use, and the future of vasopressin in pediatr

259 -year) survival, symptomatic VT control, and amiodarone use.

260 ions were more pronounced in the subgroup of amiodarone users, in which 3 SNPs, including rs10800397,

261 sotalol (HR 1.72; 1.17-2.54), but lower with amiodarone versus Class Ic (HR 0.68; 0.57-0.80) and sota

262 e events requiring drug discontinuation with amiodarone versus dronedarone (OR: 1.81; 95% CI: 1.33 to

263 The effect of amiodarone versus dronedarone was summarized by the use

264 oints (95% CI, -1.0 to 6.3; P=0.16); and for amiodarone versus lidocaine, 0.7 percentage points (95%

265 ant estimated reduction in recurrent AF with amiodarone versus placebo (odds ratio [OR]: 0.12; 95% co

266 The difference in survival rate for amiodarone versus placebo was 3.2 percentage points (95%

267 nshockable-turned-shockable arrhythmias with amiodarone versus placebo were 2.3% (-0.3, 4.8), P=0.08,

268 non-CV death being significantly higher with amiodarone versus Rate (HR: 1.11, 95% CI: 1.01 to 1.24,

269 mended initial 300-mg intravenous bolus, and amiodarone was administered an average of 8 mins later i

270 ncy warned that bradycardia could occur when amiodarone was administered in combination with sofosbuv

271 As compared with placebo, amiodarone was associated with a similar risk of death (

272 Among patients who survived 3 hrs, amiodarone was associated with increased mortality at 30

273 ponse study of the safety and efficacy of IV amiodarone was conducted in 61 children (30 days to 14.9

274 From this spatial analysis, amiodarone was detected throughout the cell, with the ma

275 The dose of amiodarone was increased if it had been less than 300 mg

276 In the escalated-therapy group, amiodarone was initiated if another agent had been used

277 IKAS inhibition by amiodarone was not voltage-dependent, but was Ca(2+)-dep

278 A similar effect of amiodarone was observed when pilocarpine was used to sti

279 tion of the HCV-NS5B prodrug sofosbuvir with amiodarone was recently reported.

280 Amiodarone was searched using the terms adverse effects,

281 rtion of the substudy was stopped early when amiodarone was shown to be better than class I agents.

282 Amiodarone was superior to sotalol (P<0.001) and to plac

283 interaction between randomized treatment and amiodarone was tested using a Cox model, with main effec

284 ajority of JET patients (89%), and of those, amiodarone was the most commonly reported effective agen

285 Amiodarone was the most frequently used medication alone

286 Amiodarone was the primary treatment in 63% of cases, 1%

287 Intravenous amiodarone was used in 46%, electric cardioversion in 28

288 time to prescription of recovery medication (amiodarone) was the only parameter showing an intergroup

289 patients treated with dronedarone instead of amiodarone, we estimate approximately 228 more recurrenc

290 Placebo and amiodarone were administered in a double-blind fashion.

291 s III anti-arrhythmic agents vernakalant and amiodarone were introduced in the model by inhibiting ap

292 Genes down-regulated by amiodarone were involved in all stages of cell cycle con

293 Both vernakalant and amiodarone were safe and well tolerated in this study.

294 r (ICD) therapy and appeared to be harmed by amiodarone, whereas New York Heart Association functiona

295 ximal inhibition was observed with 50 microM amiodarone which inhibited 85.6 +/- 3.1% of IKAS induced

296 nd HepG2 cells uptake the greatest amount of amiodarone with an average of 2.38 and 2.60 pg per cell,

297 l with cardiovascular outcomes that compares amiodarone with placebo in patients already receiving be

298 randomized trial, we compared ICD therapy or amiodarone with state-of-the-art medical therapy alone i

299 The majority of genes induced by amiodarone within 10 min were involved in utilization of

300 1 show growth sensitivity to multiple drugs (amiodarone, wortmannin, sulfometuron methyl, and tunicam